Literature DB >> 27281337

Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.

Claire Williams1, James D Lewsey1, Andrew H Briggs1, Daniel F Mackay2.   

Abstract

This tutorial provides a step-by-step guide to performing cost-effectiveness analysis using a multi-state modeling approach. Alongside the tutorial, we provide easy-to-use functions in the statistics package R. We argue that this multi-state modeling approach using a package such as R has advantages over approaches where models are built in a spreadsheet package. In particular, using a syntax-based approach means there is a written record of what was done and the calculations are transparent. Reproducing the analysis is straightforward as the syntax just needs to be run again. The approach can be thought of as an alternative way to build a Markov decision-analytic model, which also has the option to use a state-arrival extended approach. In the state-arrival extended multi-state model, a covariate that represents patients' history is included, allowing the Markov property to be tested. We illustrate the building of multi-state survival models, making predictions from the models and assessing fits. We then proceed to perform a cost-effectiveness analysis, including deterministic and probabilistic sensitivity analyses. Finally, we show how to create 2 common methods of visualizing the results-namely, cost-effectiveness planes and cost-effectiveness acceptability curves. The analysis is implemented entirely within R. It is based on adaptions to functions in the existing R package mstate to accommodate parametric multi-state modeling that facilitates extrapolation of survival curves.

Entities:  

Keywords:  Markov models; cost-effectiveness analysis; probabilistic sensitivity analysis; survival analysis

Mesh:

Substances:

Year:  2016        PMID: 27281337      PMCID: PMC5424858          DOI: 10.1177/0272989X16651869

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  12 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Tutorial in biostatistics: competing risks and multi-state models.

Authors:  H Putter; M Fiocco; R B Geskus
Journal:  Stat Med       Date:  2007-05-20       Impact factor: 2.373

3.  Decision-analytical modelling in health-care economic evaluations.

Authors:  Xin Sun; Thomas Faunce
Journal:  Eur J Health Econ       Date:  2007-10-18

4.  Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play.

Authors:  Richard Grieve; Neil Hawkins; Mark Pennington
Journal:  Med Decis Making       Date:  2013-08       Impact factor: 2.583

5.  Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R.

Authors:  Gerardus W J Frederix; Johan G C van Hasselt; Johan L Severens; Anke M Hövels; Alwin D R Huitema; Jan A M Raaijmakers; Jan H M Schellens
Journal:  Med Decis Making       Date:  2013-03-20       Impact factor: 2.583

6.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

7.  The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models.

Authors:  Liesbeth C de Wreede; Marta Fiocco; Hein Putter
Journal:  Comput Methods Programs Biomed       Date:  2010-03-15       Impact factor: 5.428

8.  Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response.

Authors:  Neil Hawkins; Mark Sculpher; David Epstein
Journal:  Med Decis Making       Date:  2005 Sep-Oct       Impact factor: 2.583

9.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

10.  Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.

Authors:  Elisabeth Fenwick; Deborah A Marshall; Adrian R Levy; Graham Nichol
Journal:  BMC Health Serv Res       Date:  2006-04-19       Impact factor: 2.655

View more
  19 in total

Review 1.  Economic Evaluations of Mental Health Programs for Children and Adolescents in the United States: A Systematic Review.

Authors:  Jenna Y Sung; Corinne N Kacmarek; Jessica L Schleider
Journal:  Clin Child Fam Psychol Rev       Date:  2021-01-11

Review 2.  Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Authors:  Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

3.  Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Authors:  Jaclyn Beca; Don Husereau; Kelvin K W Chan; Neil Hawkins; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

4.  Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout Session.

Authors:  Henry J Henk; Ya-Chen Tina Shih; Bijan J Borah
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

5.  Identification of a Novel Risk Model: A Five-Gene Prognostic Signature for Pancreatic Cancer.

Authors:  Xiaoguang Wang; Man Ni; Daxiong Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-08       Impact factor: 2.650

6.  Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.

Authors:  Vaibhav Kumar; Joshua T Cohen; David van Klaveren; Djøra I Soeteman; John B Wong; Peter J Neumann; David M Kent
Journal:  Ann Intern Med       Date:  2018-01-02       Impact factor: 25.391

7.  Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Authors:  Beth S Woods; Eleftherios Sideris; Matthew R Sydes; Melissa R Gannon; Mahesh K B Parmar; Mymoona Alzouebi; Gerhardt Attard; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir R Chakraborti; Audrey Cook; William R Cross; David P Dearnaley; Joanna Gale; Stephanie Gibbs; John D Graham; Robert Hughes; Rob J Jones; Robert Laing; Malcolm D Mason; David Matheson; Duncan B McLaren; Robin Millman; Joe M O'Sullivan; Omi Parikh; Christopher C Parker; Clive Peedell; Andrew Protheroe; Alastair W S Ritchie; Angus Robinson; J Martin Russell; Matthew S Simms; Narayanan N Srihari; Rajaguru Srinivasan; John N Staffurth; Santhanam Sundar; George N Thalmann; Shaun Tolan; Anna T H Tran; David Tsang; John Wagstaff; Nicholas D James; Mark J Sculpher
Journal:  Eur Urol Oncol       Date:  2018-09-14

8.  Correlated multistate models for multiple processes: an application to renal disease progression in systemic lupus erythematosus.

Authors:  Aidan G O'Keeffe; Li Su; Vernon T Farewell
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-01-08       Impact factor: 1.864

9.  Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.

Authors:  Claire Williams; James D Lewsey; Daniel F Mackay; Andrew H Briggs
Journal:  Med Decis Making       Date:  2016-10-04       Impact factor: 2.583

10.  An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.

Authors:  Arielle G Bensimon; Zheng-Yi Zhou; Madeline Jenkins; Yan Song; Wei Gao; James Signorovitch; Clemens Krepler; Emilie Scherrer; Jingshu Wang; Raquel Aguiar-Ibáñez
Journal:  Clin Drug Investig       Date:  2020-07       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.